Skip to content

Effects of Nigella Sativa oil supplementation on Glucose and Lipid Profile Indices in Patients with Type 2 Diabetes.

Investigation the effect of Nigella Sativa oil on Glucose and Lipid Profile control in Patients with Type 2 Diabetes.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013090814588N1
Enrollment
72
Registered
2014-04-29
Start date
2014-04-09
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: Comsumption of 3 gr/day Nigella Sativa oil provided by Barij pharmaceutical company(1 gr soft gel capsule 3 times a day) for 3 months. Intervention 2: Control grou
Treatment - Drugs
Placebo
Intervention group: Comsumption of 3 gr/day Nigella Sativa oil provided by Barij pharmaceutical company(1 gr soft gel capsule 3 times a day) for 3 months
Control group: 3 gr/day sunflower oil provided by Barij pharmaceutical company(1 gr soft gel capsule 3 times a day) for 3 months

Sponsors

Barij Esans Pharma Industries
Lead Sponsor
Kermanshah University Of Medical Sciences
Collaborator

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1-type 2 diabetes patients, 2-taking routine diabetes drugs Exclusion Criteria: 1- taking insulin patients, 2- Cardiovascular, Renal, thyroid dysfunctions and liver diseases patients, 3-patients who taking anti coagulant drugs like Aspirin, Vitamin E and other Herbal drugs, 4-pregnant and lactating women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting blood sugar(FBS). Timepoint: beginning and end of the study. Method of measurement: blood sample.;Glycated hemoglubin(hba1c). Timepoint: beginning and end of the study. Method of measurement: blood sample.;Total cholestrol(TC). Timepoint: beginning and end of the study. Method of measurement: blood sample.;High density lipoprotein (HDL). Timepoint: beginning and end of the study. Method of measurement: blood sample.;Triglyceride (TG). Timepoint: beginning and end of the study. Method of measurement: blood sample.;Low density lipoproteins (LDL). Timepoint: beginning and end of the study. Method of measurement: blood sample.

Secondary

MeasureTime frame
Height. Timepoint: beginning and end of the study. Method of measurement: Height Gauges.;?Weight. Timepoint: beginning and end of the study. Method of measurement: Scale.;Waist Circumference. Timepoint: beginning and end of the study. Method of measurement: tape.;Hip Circumference. Timepoint: beginning and end of the study. Method of measurement: tape.;Blood pressure. Timepoint: beginning and end of the study. Method of measurement: pressure meter.;Diet. Timepoint: beginning and end of the study. Method of measurement: 24 hour food recall.;Physical Activity. Timepoint: beginning and end of the study. Method of measurement: physical activity questionaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Heshmati

Kermanshah University of medical science

Javad.heshmati@gmail.com+98 83 8423 1045

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026